Shacubatril And Valsartan Sodium API

Name	Shacubatril and Valsartan Sodium
Chinese name	沙库巴曲缬沙坦钠
Cas Number	936623-90-4
Source	India
Qualifications	USDMF/-/-/-/-

Sacubitril and Valsartan Sodium contains enkephalinase inhibitor (ARNI) Sacubazir and angiotensin receptor antagonist valsartan, as a breakthrough innovative drug for the treatment of chronic heart failure in the past 20 years, SAKU Baltrovalsartan sodium tablets is also the world’s first ARNI drug for the treatment of patients with chronic heart failure (NYHA II-IV). It was first reviewed and listed by the National Food and Drug Administration in 2017 and has benefited 70 Ten thousand Chinese patients with heart failure. The "2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure" recommends the innovative drug angiotensin receptor enkephalinase inhibitor (ARNI) as a class of drugs. This update is mainly based on the outstanding clinical manifestations of ARNI drugs. Studies have shown that compared with enalapril, sacubitril/valsartan can significantly reduce the risk of cardiovascular death in patients with heart failure with reduced ejection fraction by 20%, hospitalization due to heart failure by 21%, and all-cause mortality 16 %. This product brought Novartis' sales revenue of US$1.726 billion in 2019. Sacubitril and Valsartan Sodium is included in the 2019 China Medical Insurance Category B list.

Hot Tags: shacubatril and valsartan sodium api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Perindopril Arginine API, Lercanidipine Hydrochloride API, Dimethyl Fumarate API, Temozolomide API, Active Pharmaceutical Ingredient, Celecoxib API

• Previous: Davapyridine API
• Next: Gestodene API